



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts

Public declaration of interests

I, **Heinz Wiendl**

Organisation/Company: Universitaetsklinikum Muenster

Country: Germany

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
07/2017-(current)	Biogen	disease-modifying treatment of multiple sclerosis	
07/2017-(current)	Novartis	disease-modifying treatment of multiple sclerosis, Biomarker for treatment response	
07/2017-01/2022	Genzyme	disease-modifying treatment of multiple sclerosis	
07/2017-(current)	Merck	disease-modifying treatment of multiple sclerosis	
07/2017-(current)	Roche	disease-modifying treatment of multiple sclerosis	
07/2017-(current)	Sanofi-aventis	disease-modifying treatment of multiple sclerosis	
04/2020-09/2020	Biologix	DMTs to treat Multiple Sclerosis during Covid-19 pandemia	
05/2020-12/2021	Abbvie	Neurorestoration	
06/2020-06/2020	Diaplan	MS therapies and Covid-19	
11/2020-11/2020	Nexgen	Multiple Sclerosis	
03/2021-03/2021	Gen Medicine	Plegridy	Multiple Sclerosis
09/2021-09/2021	Amicus	differential diagnosis of multiple sclerosis	
06/2022-(current)	Alexion	Diagnosis and Therapy of Myasthenia gravis	
09/2018-(current)	Bristol Myers Squibb/Celgene	Therapy of Multiple Sclerosis	
11/2022-11/2022	TEVA	Therapy of Multiple Sclerosis	
01/2022-(current)	Argenx	generalized myasthenia gravis	
03/2022-(current)	Gossamer Bio	neuroinflammatory and/or neuro-degenerative diseases	

Classified as public by the European Medicines Agency

11/2020-(current)	Idorsia	multiple sclerosis
07/2021-(current)	Immunovant	myasthenia gravis
05/2020-(current)	UCB Biopharma SRL	MG disease and therapeutic environment
03/2022-(current)	Worldwide Clinical Trials Limited	neuroinflammatory and/or neuro-degenerative diseases

2.3 Strategic advisory role

Period	Company	Products	Therapeutic Indication
12/2016-(current)	Alexion	treatment of myasthenia gravis	
01/2017-12/2021	Actelion	S1P modulator Ponesimod	multiple sclerosis and other autoimmune diseases
05/2018-(current)	Immunic AG	P2-IMU-838-MS	treatment of multiple sclerosis
04/2018-12/2021	Lohmann Therapie-Systeme	treatment of multiple sclerosis	
11/2018-01/2022	Biogen	disease-modifying therapies of multiple sclerosis	
05/2019-(current)	EMD Serono	Evobrutinib	multiple sclerosis
06/2017-(current)	Merck	Mavenclad	multiple sclerosis
04/2017-(current)	Roche	disease-modifying treatment for multiple sclerosis	
11/2019-12/2021	PSI CRO Deutschland GmbH	biosimilar natalizumab	multiple sclerosis
06/2020-06/2020	Ogilvy	zilucoplan and rozimab	Myasthenia gravis
11/2020-(current)	Janssen Pharmaceuticals	RMS, MG, chronic inflammatory demyelinating polyneuropathy, idiopathic inflammatory myopathies	
01/2020-(current)	Argenx	treatment of generalized myasthenia gravis	
05/2020-(current)	EMD Serono	Evobrutinib	multiple sclerosis
09/2021-09/2021	Inmune	NMOSD	
01/2022-(current)	Novartis	Multiple Sclerosis Therapy	
09/2022-(current)	Hexal-Sandoz	Multiple Sclerosis Therapy	
10/2022-(current)	Becton Dickinson Benelux	Multiple Sclerosis (MS) in relation to patient stratification and therapeutic monitoring	

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
07/2012-(current)	Novartis	Siponimod	multiple sclerosis

2.6 Investigator

Period	Company	Products	Therapeutic Indication
12/2017-12/2018	Biogen	Opicinumab	multiple sclerosis
10/2018-(current)	Merck	Mavenclad	multiple sclerosis
01/2022-(current)	Argenx	Efgartigimod	generalized Myasthenia gravis (2020-004086-38)
01/2022-(current)	Biogen	none: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MSPATHS)	Multiple sclerosis (888MS001 and 888MS002)
12/2021-(current)	CSL Behring	IgPro (subcutaneous immunoglobuline)	Dermatomyositis (2018-003171-35)
10/2021-(current)	Roche	RO7121932	multiple sclerosis
06/2022-(current)	Roche	Satralizumab	generalized myasthenia gravis (2020-004436-21)
01/2022-(current)	UCB	Rozanilizumab	generalized myasthenia gravis (2019-000968-18 and 2019-000969-21)

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Biogen, Genzyme, Merck, Novartis, Roche, TEVA	diverse scientific projects

2.8 Close family member interest

No interest declared

2.9 Repurposing of a medicinal product

No interest declared

2.10 Any other interests or facts

ECTRIMS: Member of the guideline committee and the ECTRIMS council
 German Neurological Society (DGN): member of the guideline committees for multiple sclerosis, myasthenia gravis and myositis

2.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

CONFIDENTIALITY UNDERTAKING

Classified as public by the European Medicines Agency

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Heinz Wiendl
Date:	2022-11-21

For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template